User login
Key clinical point: Older patients with advanced myelodysplastic syndrome (MDS) may benefit from allogeneic hematopoietic cell transplantation (HCT), which is usually reserved for younger patients.
Major finding: At 3 years, the donor vs no-donor group had a greater improvement in overall survival (absolute difference, 21.3%; P = .0001) and higher leukemia-free survival (35.8% vs 20.6%; P = .003).
Study details: The study included patients aged 50-75 years with newly diagnosed MDS of higher risk and who were eligible for reduced-intensity conditioning (RIC) allogeneic HCT. Patients were initially assigned to the "no-donor" group at enrollment and reassigned to the donor group when a suitable donor was identified.
Disclosures: No specific funding information was available for the study. The authors reported relationships with various pharmaceutical companies and/or research organizations.
Source: Nakamura R et al. ASH 2020. 2020 Dec 5. Abstract 75.
Key clinical point: Older patients with advanced myelodysplastic syndrome (MDS) may benefit from allogeneic hematopoietic cell transplantation (HCT), which is usually reserved for younger patients.
Major finding: At 3 years, the donor vs no-donor group had a greater improvement in overall survival (absolute difference, 21.3%; P = .0001) and higher leukemia-free survival (35.8% vs 20.6%; P = .003).
Study details: The study included patients aged 50-75 years with newly diagnosed MDS of higher risk and who were eligible for reduced-intensity conditioning (RIC) allogeneic HCT. Patients were initially assigned to the "no-donor" group at enrollment and reassigned to the donor group when a suitable donor was identified.
Disclosures: No specific funding information was available for the study. The authors reported relationships with various pharmaceutical companies and/or research organizations.
Source: Nakamura R et al. ASH 2020. 2020 Dec 5. Abstract 75.
Key clinical point: Older patients with advanced myelodysplastic syndrome (MDS) may benefit from allogeneic hematopoietic cell transplantation (HCT), which is usually reserved for younger patients.
Major finding: At 3 years, the donor vs no-donor group had a greater improvement in overall survival (absolute difference, 21.3%; P = .0001) and higher leukemia-free survival (35.8% vs 20.6%; P = .003).
Study details: The study included patients aged 50-75 years with newly diagnosed MDS of higher risk and who were eligible for reduced-intensity conditioning (RIC) allogeneic HCT. Patients were initially assigned to the "no-donor" group at enrollment and reassigned to the donor group when a suitable donor was identified.
Disclosures: No specific funding information was available for the study. The authors reported relationships with various pharmaceutical companies and/or research organizations.
Source: Nakamura R et al. ASH 2020. 2020 Dec 5. Abstract 75.